US FDA shows flexibility on unapproved opioids ban
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration, as it moves ahead with its initiative to ensure that all drugs available on the market meet required standards for safety and efficacy, has temporarily allowed seven companies to continue the marketing and distribution of an unapproved opioid drug1. The drug in question is a high-concentrate morphine sulfate oral solution that is widely used to alleviate pain in terminally ill patients.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.